SOURCE: Vista Partners LLC

Vista Partners LLC

April 17, 2012 09:15 ET

Vista Partners Initiates Coverage on Ohr Pharmaceutical, Inc.; Target Price $2.20

SAN FRANCISCO, CA--(Marketwire - Apr 17, 2012) - Vista Partners announced today that it has initiated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month target price of $2.20. Ross Silver, Principal Analyst at Vista Partners, stated, "Anti-VEGF therapies such as ranibizumab (Lucentis®) and bevacizumab (Avastin®) both of which are sold in the U.S. by Genentech (acquired by Roche), as well as, Regeneron's recently approved (November 2011) aflibercept (Eylea®) intravitreal injections, have become the market leaders in treating age-related macular degeneration (AMD). Numerous sources cite that the wet AMD market represents a $3B+ opportunity worldwide, with great potential for expansion with new treatment alternatives and combination therapies. OHR's wet AMD clinical candidate Squalamine, which is intended to be delivered via eye drop, had previously been evaluated for the treatment of wet-AMD using an intravenous formulation in over 250 patients. According to the Company, the previously completed clinical trials demonstrated that the molecule had biologic effect and maintained and improved visual acuity outcomes, with both early and advanced lesions responding."

To download a FREE copy of the Ohr Pharmaceutical, Inc. research report, please visit and click the "Download" icon to gain access to the report.

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more...

Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website

Contact Information